Starpharma combination Dep Irinotecan and folfiri trial results is just what might make onivyde redundant
The global pancreatic cancer therapy market is expected to reach US$ 4,056.4 Mn in 2025 from US$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8.1% from 2018-2025.
The growth of the pancreatic cancer therapy market is primarily attributed to the increase in number of therapies launched in the market. The development of new drugs is thus expected to drive the growth of pancreatic cancer therapy market. For instance, in October 2015, the FDA approved Onivyde drug by Merrimack Pharmaceuticals, Inc. as a part of treatment regimen for advanced pancreatic cancer. Some common side effects associated with chemotherapy drugs include diarrhea and abdominal cramping, fatigue, loss of appetite, change in food taste and others. Cancer cells that are rapidly growing are killed by chemotherapy drugs.
However, these drugs travel throughout the body and thus can affect normal and healthy cells adversely. Blood-forming cells in the bone marrow, hair follicles and cell in the mouth, digestive tract, and reproductive system are likely to be affected by chemotherapeutic drugs. The current treatment options available for pancreatic cancer patients only help to extend the patients' lives by a few months.
This demands potential drugs that are able to enhance the effectiveness of chemotherapy drugs. Combination of two or more chemotherapy drugs are a suitable way out to increase the efficacy of the drug as well as proves advantageous in the treatment
SPL Price at posting:
13.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)